Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma
Authors:
- Brian DeBDBrian De
- Ibrahim Abu-GheidaIAIbrahim Abu-Gheida
- Aashini PatelAPAashini Patel
- Sylvia S. W. NgSNSylvia S. W. Ng
- Mohamed ZaidMZMohamed Zaid
- Connor P. ThunshelleCTConnor P. Thunshelle
- Dalia ElganainyDEDalia Elganainy
- Kelsey L. CorriganKCKelsey L. Corrigan
- Michael K. RooneyMRMichael K. Rooney
- Milind JavleMJMilind Javle
- Kanwal RaghavKRKanwal Raghav
- Sunyoung S. LeeSLSunyoung S. Lee
Open Access
- 1 December 2021
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 11 (12) , 1270
Abstract
We have previously shown that ablative radiotherapy (A-RT) with a biologically effective dose (BED10) ≥ 80.5 Gy for patients with unresectable intrahepatic cholangiocarcinoma (ICC) is associated with longer survival. Despite recent large-scale sequencing efforts in ICC, outcomes following RT based on genetic alterations have not been described. We reviewed records of 156 consecutive patients treated with A-RT for unresectable ICC from 2008 to 2020. For 114 patients (73%), next-generation sequencing provided molecular profiles. The overall survival (OS), local control (LC), and distant metastasis-free survival (DMFS) were estimated using the Kaplan–Meier method. Univariate and multivariable Cox analyses were used to determine the associations with the outcomes. The median tumor size was 7.3 (range: 2.2–18.2) cm. The portal vein thrombus (PVT) was present in 10%. The RT median BED10 was 98 Gy (range: 81–144 Gy). The median (95% confidence interval) follow-up was 58 (42–104) months from diagnosis and 39 (33–74) months from RT. The median OS was 32 (29–35) months after diagnosis and 20 (16–24) months after RT. The one-year OS, LC, and intrahepatic DMFS were 73% (65–80%), 81% (73–87%), and 34% (26–42%). The most common mutations were in IDH1 (25%), TP53 (22%), ARID1A (19%), and FGFR2 (13%). Upon multivariable analysis, the factors associated with death included worse performance status, larger tumor, metastatic disease, higher CA 19-9, PVT, satellitosis, and IDH1 and PIK3CA mutations. TP53 mutation was associated with local failure. Further investigation into the prognostic value of individual mutations and combinations thereof is warranted.Keywords
Funding Information
- National Cancer Institute (P30 CA016672, U54CA210181-01, U01CA200468, U01CA196403)
- Radiological Society of North America (RR2111, RSD1429)
This publication has 43 references indexed in Scilit:
- Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisJournal of Clinical Oncology, 2016
- Genomic spectra of biliary tract cancerNature Genetics, 2015
- Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic TargetsAnnals of Surgical Oncology, 2014
- Identification of Targetable FGFR Gene Fusions in Diverse CancersCancer Discovery, 2013
- Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different OutcomesGastroenterology, 2013
- Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase InhibitorsGastroenterology, 2012
- Isocitrate Dehydrogenase 1 and 2 Mutations in Cancer: Alterations at a Crossroads of Cellular MetabolismJNCI: Journal of the National Cancer Institute, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerNew England Journal of Medicine, 2010
- The role of chemotherapy in cholangiocarcinomaAnnals of Oncology, 2005
- Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United StatesHepatology, 2001